Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1996 Mar;5(3):422–433. doi: 10.1002/pro.5560050303

Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic.

R Krishnan 1, A Tulinsky 1, G P Vlasuk 1, D Pearson 1, P Vallar 1, P Bergum 1, T K Brunck 1, W C Ripka 1
PMCID: PMC2143369  PMID: 8868478

Abstract

A new class of divalent thrombin inhibitors is described that contains an alpha-keto-amide transition-state mimetic linking an active site binding group and a group that binds to the fibrinogen-binding exosite. The X-ray crystallographic structure of the most potent member of this new class, CVS995, shows many features in common with other divalent thrombin inhibitors and clearly defines the transition-state-like binding of the alpha-keto-amide group. The structure of the active site part of the inhibitor shows a network of water molecules connecting both the side-chain and backbone atoms of thrombin and the inhibitor. Direct peptide analogues of the new transition-state-containing divalent thrombin inhibitors were compared using in vitro assays of thrombin inhibition. There was no direct correlation between the binding constants of the peptides and their alpha-keto-amide counterparts. The most potent alpha-keto-amide inhibitor, CVS995, with a Ki = 1 pM, did not correspond to the most potent divalent peptide and contained a single amino acid deletion in the exosite binding region with respect to the equivalent region of the natural thrombin inhibitor hirudin. The interaction energies of the active site, transition state, and exosite binding regions of these new divalent thrombin inhibitors are not additive.

Full Text

The Full Text of this article is available as a PDF (7.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banner D. W., Hadváry P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem. 1991 Oct 25;266(30):20085–20093. [PubMed] [Google Scholar]
  2. Betz A., Hofsteenge J., Stone S. R. Role of interactions involving C-terminal nonpolar residues of hirudin in the formation of the thrombin-hirudin complex. Biochemistry. 1991 Oct 15;30(41):9848–9853. doi: 10.1021/bi00105a006. [DOI] [PubMed] [Google Scholar]
  3. Bode W., Mayr I., Baumann U., Huber R., Stone S. R., Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989 Nov;8(11):3467–3475. doi: 10.1002/j.1460-2075.1989.tb08511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992 Apr;1(4):426–471. doi: 10.1002/pro.5560010402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DiMaio J., Gibbs B., Lefebvre J., Konishi Y., Munn D., Yue S. Y., Hornberger W. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem. 1992 Sep 4;35(18):3331–3341. doi: 10.1021/jm00096a004. [DOI] [PubMed] [Google Scholar]
  6. DiMaio J., Gibbs B., Munn D., Lefebvre J., Ni F., Konishi Y. Bifunctional thrombin inhibitors based on the sequence of hirudin45-65. J Biol Chem. 1990 Dec 15;265(35):21698–21703. [PubMed] [Google Scholar]
  7. DiMaio J., Ni F., Gibbs B., Konishi Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Lett. 1991 Apr 22;282(1):47–52. doi: 10.1016/0014-5793(91)80441-5. [DOI] [PubMed] [Google Scholar]
  8. Ehrlich H. J., Grinnell B. W., Jaskunas S. R., Esmon C. T., Yan S. B., Bang N. U. Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin. EMBO J. 1990 Aug;9(8):2367–2373. doi: 10.1002/j.1460-2075.1990.tb07411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Esmon C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989 Mar 25;264(9):4743–4746. [PubMed] [Google Scholar]
  10. Fenton J. W., 2nd Thrombin specificity. Ann N Y Acad Sci. 1981;370:468–495. doi: 10.1111/j.1749-6632.1981.tb29757.x. [DOI] [PubMed] [Google Scholar]
  11. Fenton J. W., 2nd Thrombin. Ann N Y Acad Sci. 1986;485:5–15. doi: 10.1111/j.1749-6632.1986.tb34563.x. [DOI] [PubMed] [Google Scholar]
  12. Grütter M. G., Priestle J. P., Rahuel J., Grossenbacher H., Bode W., Hofsteenge J., Stone S. R. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J. 1990 Aug;9(8):2361–2365. doi: 10.1002/j.1460-2075.1990.tb07410.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hendrickson W. A. Stereochemically restrained refinement of macromolecular structures. Methods Enzymol. 1985;115:252–270. doi: 10.1016/0076-6879(85)15021-4. [DOI] [PubMed] [Google Scholar]
  14. Ishii K., Gerszten R., Zheng Y. W., Welsh J. B., Turck C. W., Coughlin S. R. Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate. J Biol Chem. 1995 Jul 7;270(27):16435–16440. doi: 10.1074/jbc.270.27.16435. [DOI] [PubMed] [Google Scholar]
  15. Kline T., Hammond C., Bourdon P., Maraganore J. M. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1049–1055. doi: 10.1016/0006-291x(91)90644-m. [DOI] [PubMed] [Google Scholar]
  16. Lewis S. D., Ng A. S., Baldwin J. J., Fusetani N., Naylor A. M., Shafer J. A. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A. Thromb Res. 1993 Apr 15;70(2):173–190. doi: 10.1016/0049-3848(93)90158-k. [DOI] [PubMed] [Google Scholar]
  17. Maraganore J. M., Bourdon P., Jablonski J., Ramachandran K. L., Fenton J. W., 2nd Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990 Jul 31;29(30):7095–7101. doi: 10.1021/bi00482a021. [DOI] [PubMed] [Google Scholar]
  18. Maraganore J. M. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemost. 1993 Jul 1;70(1):208–211. [PubMed] [Google Scholar]
  19. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost. 1989 Jul;15(3):269–282. doi: 10.1055/s-2007-1002719. [DOI] [PubMed] [Google Scholar]
  20. Martin P. D., Robertson W., Turk D., Huber R., Bode W., Edwards B. F. The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem. 1992 Apr 15;267(11):7911–7920. [PubMed] [Google Scholar]
  21. Maryanoff B. E., Qiu X., Padmanabhan K. P., Tulinsky A., Almond H. R., Jr, Andrade-Gordon P., Greco M. N., Kauffman J. A., Nicolaou K. C., Liu A. Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8048–8052. doi: 10.1073/pnas.90.17.8048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mathews I. I., Padmanabhan K. P., Ganesh V., Tulinsky A., Ishii M., Chen J., Turck C. W., Coughlin S. R., Fenton J. W., 2nd Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994 Mar 22;33(11):3266–3279. doi: 10.1021/bi00177a018. [DOI] [PubMed] [Google Scholar]
  23. Priestle J. P., Rahuel J., Rink H., Tones M., Grütter M. G. Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms. Protein Sci. 1993 Oct;2(10):1630–1642. doi: 10.1002/pro.5560021009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Qiu X., Padmanabhan K. P., Carperos V. E., Tulinsky A., Kline T., Maraganore J. M., Fenton J. W., 2nd Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. Biochemistry. 1992 Dec 1;31(47):11689–11697. doi: 10.1021/bi00162a004. [DOI] [PubMed] [Google Scholar]
  25. Qiu X., Yin M., Padmanabhan K. P., Krstenansky J. L., Tulinsky A. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J Biol Chem. 1993 Sep 25;268(27):20318–20326. [PubMed] [Google Scholar]
  26. Rydel T. J., Ravichandran K. G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton J. W., 2nd The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990 Jul 20;249(4966):277–280. doi: 10.1126/science.2374926. [DOI] [PubMed] [Google Scholar]
  27. Sadler J. E., Lentz S. R., Sheehan J. P., Tsiang M., Wu Q. Structure-function relationships of the thrombin-thrombomodulin interaction. Haemostasis. 1993 Mar;23 (Suppl 1):183–193. doi: 10.1159/000216927. [DOI] [PubMed] [Google Scholar]
  28. Skrzypczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol. 1991 Oct 20;221(4):1379–1393. [PubMed] [Google Scholar]
  29. Stenflo J., Fernlund P. Amino acid sequence of the heavy chain of bovine protein C. J Biol Chem. 1982 Oct 25;257(20):12180–12190. [PubMed] [Google Scholar]
  30. Stubbs M. T., Oschkinat H., Mayr I., Huber R., Angliker H., Stone S. R., Bode W. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem. 1992 May 15;206(1):187–195. doi: 10.1111/j.1432-1033.1992.tb16916.x. [DOI] [PubMed] [Google Scholar]
  31. Szewczuk Z., Gibbs B. F., Yue S. Y., Purisima E. O., Konishi Y. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion. Biochemistry. 1992 Sep 29;31(38):9132–9140. doi: 10.1021/bi00153a004. [DOI] [PubMed] [Google Scholar]
  32. Szewczuk Z., Gibbs B. F., Yue S. Y., Purisima E., Zdanov A., Cygler M., Konishi Y. Design of a linker for trivalent thrombin inhibitors: interaction of the main chain of the linker with thrombin. Biochemistry. 1993 Apr 6;32(13):3396–3404. doi: 10.1021/bi00064a025. [DOI] [PubMed] [Google Scholar]
  33. Tulinsky A., Blevins R. A. Structure of a tetrahedral transition state complex of alpha-chymotrypsin dimer at 1.8-A resolution. J Biol Chem. 1987 Jun 5;262(16):7737–7743. doi: 10.2210/pdb6cha/pdb. [DOI] [PubMed] [Google Scholar]
  34. Tulinsky A., Qiu X. Active site and exosite binding of alpha-thrombin. Blood Coagul Fibrinolysis. 1993 Apr;4(2):305–312. doi: 10.1097/00001721-199304000-00012. [DOI] [PubMed] [Google Scholar]
  35. Vu T. K., Hung D. T., Wheaton V. I., Coughlin S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991 Mar 22;64(6):1057–1068. doi: 10.1016/0092-8674(91)90261-v. [DOI] [PubMed] [Google Scholar]
  36. Vu T. K., Wheaton V. I., Hung D. T., Charo I., Coughlin S. R. Domains specifying thrombin-receptor interaction. Nature. 1991 Oct 17;353(6345):674–677. doi: 10.1038/353674a0. [DOI] [PubMed] [Google Scholar]
  37. Wilcox J. N., Rodriguez J., Subramanian R., Ollerenshaw J., Zhong C., Hayzer D. J., Horaist C., Hanson S. R., Lumsden A., Salam T. A. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994 Dec;75(6):1029–1038. doi: 10.1161/01.res.75.6.1029. [DOI] [PubMed] [Google Scholar]
  38. Williams J. W., Morrison J. F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 1979;63:437–467. doi: 10.1016/0076-6879(79)63019-7. [DOI] [PubMed] [Google Scholar]
  39. Zdanov A., Wu S., DiMaio J., Konishi Y., Li Y., Wu X., Edwards B. F., Martin P. D., Cygler M. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6. Proteins. 1993 Nov;17(3):252–265. doi: 10.1002/prot.340170304. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES